ArticleGynecologic oncology2016
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.
Article in Gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 63 citations in OpenAlex.
- PET Imaging in Vulvar Cancer: A Literature Review of the Current Evidence and Clinical Applications.Cancers · 2026Review
- Cancer of the vulva: 2025 update: FIGO Cancer Report 2025.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Recurrent vaginal squamous cell carcinoma mimicking peri-rectal abscess: The role of endoscopic ultrasound.Radiology case reports · 2025Article
- Imaging in Vulval Cancer.Cancers · 2024Review
- The potential advantages ofQuantitative imaging in medicine and surgery · 2024Article
- 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature.Journal of imaging · 2023Review
- Review
- Pelvic Exenteration for the Treatment of Locally Advanced Vulvar Cancer in South West Wales.Cancers · 2022Article
- Clinical and prognosticJapanese journal of radiology · 2022Article
- Gynecologic tumor board: a radiologist's guide to vulvar and vaginal malignancies.Abdominal radiology (New York) · 2021Review
- Current update on vaginal malignancies.Abdominal radiology (New York) · 2021Review
- Cancer of the vulva: 2021 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021Article
- Diagnostic performance of preoperative [European journal of nuclear medicine and molecular imaging · 2021Article
- Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT.Journal of cancer research and clinical oncology · 2020Article
- When an Unexpected Diagnosis Occurs: a Vaginal Premenopausal Sarcoma.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018Article
- 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective?Medicine · 2017Article
- Adaptive Positron Emission Tomography Radiation Therapy in Patients With Locally Advanced Vulvar Cancer: A Prospective Study.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo evaluate the changes in prognostic impression and patient management following PET/CT in patients with vulvar and vaginal carcinoma; and to compare PET/CT findings with those of conventional imaging modalities.
methodsWe summarized prospectively and retrospectively collected data for 50 consecutive patients from our institution that enrolled in the National Oncologic PET Registry and underwent FDG-PET/CT for a suspected or known primary or recurrent vulvar/vaginal cancer.
results54/83 (65%) studies included had a diagnosis of vulvar cancer, and the remaining 29/83 (35%), a diagnosis of vaginal cancer. Following FDG-PET/CT, the physician's prognostic impression changed in 51% of cases. A change in patient management, defined as a change to/from a non-interventional strategy (observation or additional imaging), to/from an interventional strategy (biopsy or treatment), was documented in 36% of studies. The electronic records demonstrated that 95% of the management strategies recorded in the physician questionnaires were implemented as planned. MRI and/or CT were performed within one month of the FDG-PET/CT in 20/83 (24%) and 28/83 (34%) cases, respectively. FDG-PET/CT detected nodes suspicious for metastases on 29/83 (35%) studies performed. MRI and CT detected positive nodes on 6 and 11 studies respectively. Distant metastases were identified in 10 cases imaged with FDG-PET and 5 cases that had additional conventional CT imaging. All suspicious lesions seen on CT were positively identified on PET/CT. In 4 cases, an abnormality identified on PET/CT, was not seen on diagnostic CT.
conclusionsFDG-PET/CT may play an important role in the management of vulvar and vaginal carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.